News & Updates
Filter by Specialty:
Atezolizumab-chemo confers durable survival benefit in ES-SCLC
In the merged analysis of the IMpower133 trial and IMbrella A open-label extension study, the combination of the PD-L1 inhibitor atezolizumab and a chemotherapy regimen comprising carboplatin and etoposide (CP/ET) demonstrated potential for survival benefit of up to 5 years in patients with extensive stage-small-cell lung cancer (ES-SCLC).
Atezolizumab-chemo confers durable survival benefit in ES-SCLC
27 Sep 2023
Calcium-channel blocker use ups glaucoma prevalence
Use of calcium-channel blockers (CCBs) appears to increase the risk of developing glaucoma, suggests a study. In addition, use of systemic beta blockers is associated with lower intraocular pressure (IOP).
Calcium-channel blocker use ups glaucoma prevalence
26 Sep 2023
Passive smoking: Does it influence risk of childhood atopic eczema, food allergy?
A systematic review and meta-analysis from Singapore demonstrates that parental smoking is not a strong risk factor for offspring eczema, food allergy, and food sensitization development.
Passive smoking: Does it influence risk of childhood atopic eczema, food allergy?
26 Sep 2023
Otilimab for RA disappoints in ContRAst 3
In the treatment of select patients with rheumatoid arthritis (RA), otilimab is neither better than placebo nor noninferior to sarilumab in terms of the proportion of patients achieving an American College of Rheumatology ≥20 percent response (ACR20), according to the results of the phase III ContRAst 3 study.